is CEO of Neuromon B.V.

In 2014, Schaafsma published the theory of Arterial Acceleration that aims to explain how the pulsatile force of the heart can reach all bodily tissues. 




Remembering is for knowledge, to understand is to forget.  Thesis. Groningen, 1991.

Neuromon B.V. aims

  • to improve medical treatment of severely ill patients
  • by providing educational and diagnostic support to medical doctors throughout the world
  • based upon a better understanding of cardiovascular physiology
  • by incorporating the Theory of Arterial Acceleration


Recently, a video was released discussing how the theory of arterial acceleration is part of the ongoing scientific quest for a better understanding of cardiovascular physiology. This quest started with Galen in the 2nd century, is greatly furthered by Harvey in the 17th century as well as by various investigators at the end of the 19th century. The theory of arterial acceleration adds to conceptual thinking about the role of the arterial system in cardiovascular physiology. It challenges a too simplistic view on arterial blood pressure.





Neuromon B.V. has developed a computer simulation of the cardiovascular system aiming to improve the understanding of cardiovascular physiology. This simulation contains a number of physiological reflexes that collaborate to keep brain perfusion as constant as possible. It also demonstrates how arterial acceleration enhances the pressure wave from the heart. For more information about the model please refer to the Downloads menu.

On this page you will find links to:

a demoversion of the Cardiovascular simulation (current version 2.6.0)

a manual for learning about the Cardiovascular simulation


Neuromon B.V. is licensed for the implementation of the so-called PaR-technology.

PaR-technology is a new way to express cerebral autoregulatory state by calculating a combined index based upon the continuous registration of arterial blood pressure, as the driving force, and middle cerebral artery flow velocity, as resultant.

The so-called pulsatile apparent resistance is negative when cerebral autoregulation is exhausted. Varies between 0 and 0.6 in the normal situation and increases over 0.6 in intracranial hypertension.

In the EU, PaR-technology was filed in the Netherlands, Belgium, Great Britain, France and Germany.

Outside the EU PaR-technology was filed in the EU, USA, Canada and Australia (WO2005102158A1).


EU: EP1755444A1

NL: P68461NLEP10

BE: P68461BEEP10

DE: 60 2005 056 940.5

GB: EP1755444

FR: EP1755444

USA: US2007293760A1

CA: CA2564059A1

AU: AU2005235162A1